You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
|
---|---|
Published in |
Lancet Oncology, October 2014
|
DOI | 10.1016/s1470-2045(14)70475-9 |
Pubmed ID | |
Authors |
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Pierre Kerbrat, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Sylvia Giard, David Coeffic, Philippe Bougnoux, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Juana Hernandez, Mathieu Coudert, Laurent Arnould, Alina Berriolo-Riedinger |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 38% |
Venezuela, Bolivarian Republic of | 2 | 25% |
Unknown | 3 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 63% |
Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Ecuador | 1 | <1% |
Unknown | 177 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 30 | 17% |
Student > Bachelor | 24 | 13% |
Other | 22 | 12% |
Student > Master | 16 | 9% |
Student > Ph. D. Student | 15 | 8% |
Other | 35 | 20% |
Unknown | 37 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 68 | 38% |
Biochemistry, Genetics and Molecular Biology | 11 | 6% |
Agricultural and Biological Sciences | 11 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
Nursing and Health Professions | 7 | 4% |
Other | 21 | 12% |
Unknown | 52 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2015.
All research outputs
#2,581,753
of 25,461,852 outputs
Outputs from Lancet Oncology
#2,435
of 6,901 outputs
Outputs of similar age
#29,294
of 274,513 outputs
Outputs of similar age from Lancet Oncology
#56
of 158 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,901 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,513 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.